I was using a conservative figure of 5% market share to illustrate a point. It's still conservative, and it's still valid.
Regarding taking exception to the following:
"If in fact we become the physicians choice"
Not sure what is so hard to understand about that, it's pretty straight forward.
Since marketing is to physicians not the public at large, who else's choice would matter? LMFAO
Heart attack and stroke issues are gonna do nothing but become a bigger and more serious issue until the baby boomer's have crested as the dominant age group in the demographic profile.
If INOL has any serious percentage of involvement with Plavix prescription dispensations it will be good for the company and good for the shareholders.
I encourage you or anybody to short over the next couple weeks if that is the preferred investment strategy. I really hope you or they do.
News 
Market Data 
Discover 
AI
